Why is Brawn Biotech falling/rising?

As of 07-Jul, Brawn Biotech Ltd's stock is currently priced at 19.00, reflecting a decrease of 0.99, or 4.95%. The stock has underperformed its sector by 5.4% today and has experienced a consecutive decline over the past two days, resulting in a total drop of 5%. Despite a positive performance over the past week and month, with returns of 8.70% and 15.85% respectively, the stock has significantly underperformed over the longer term, with a year-to-date decline of 10.84% and a one-year drop of 28.30%. The company's financial health is concerning, as it has reported operating losses and a negative EBITDA, indicating weak long-term fundamental strength. Additionally, the stock's liquidity appears limited, with a notable decrease in delivery volume, which suggests declining investor participation.
In the broader market context, while the Sensex has shown a slight decline of 0.20% over the past week, Brawn Biotech's recent performance contrasts sharply with the benchmark, particularly over the longer term where it has underperformed significantly. The stock's negative returns of 28.30% over the past year starkly contrast with the Sensex's positive return of 4.31%, highlighting the company's struggles relative to the market. This underperformance, coupled with the company's weak financial metrics and declining investor interest, contributes to the stock's current downward trajectory.